Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

多供应商多站点新型加速 MRI 松弛测量

• 批准号: 10677551
• 负责人: Xiaojuan Li
• 金额: $ 60.37万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10677551
• 关键词: 3-Dimensional; Acceleration; Acute; Address; Affect; Age; Atlases; Behavior Therapy; Biological Markers; Body Weight decreased; Body mass index; Calibration; Cartilage; Clinical; Clinical Protocols; Collaborations; Data; Data Analyses; Dedications; Degenerative polyarthritis; Development; Diagnosis; Diet; Disease; Disease Progression; Early Diagnosis; Early treatment; Evaluation; Exercise; Gender; Image; Impairment; Industrialization; Intervention; Magnetic Resonance Imaging; Maps; Measurement; Measures; Methods; Modeling; Morphology; Musculoskeletal; Patients; Persons; Pharmaceutical Preparations; Pilot Projects; Prevention; Prevention strategy; Prognosis; Protocols documentation; Quality of life; Reference Values; Relaxation; Risk; Scanning; Site; Source; Standardization; System; T2 weighted imaging; Techniques; Technology; Time; Travel; Uncertainty; Variant; Vendor; anterior cruciate ligament rupture; cancer imaging; cartilage degradation; clinical practice; clinical translation; early detection biomarkers; heart imaging; human subject; imaging biomarker; imaging modality; improved; joint function; liver imaging; multi-site trial; musculoskeletal imaging; neural; neuroimaging; novel; palliation; precision medicine; quantitative imaging; synergism; tool; treatment effect

PROJECT SUMMARY/ABSTRACT MRI relaxometry has been applied to improve early diagnosis and prognosis for a wide range of diseases. However, one typical obstacle of integrating quantitative MRI into clinical protocols is the long acquisition time. Furthermore, it is an essential but sometimes overlooked step to investigate quantification variability across sites and MR systems in order to validate MR imaging biomarkers and to apply the measures in large scale multi- vendor multi-site trials. Specifically, there is a lack of systematic evaluation of inter-vendor inter-site variability of T1ρ imaging, even though it has been widely applied in neural-, liver-, cardiac-, oncology-, and musculoskeletal- (MSK) imaging. Neither commercial T1ρ phantoms are available. The proposed study is addressing these significant gaps and aims to develop and cross-validate novel fast MR T1ρ and T2 imaging methods on MR systems from multiple vendors, followed by feasibility evaluation in patients at risk for osteoarthritis. Osteoarthritis (OA) affects over 27 million people in the US. No disease modifying OA drugs (DMOADs) are available, despite extensive effort. One hurdle for developing DMOADs is the lack of sensitive and reliable non-invasive biomarkers that can detect treatment effects over a short time window. Such biomarkers would also benefit clinical practice by identifying patients at risk for developing OA or at an early disease stage, when behavior modification strategies are shown to be most effective in slowing down the disease progression. There is a pressing, unmet clinical need for robust assessment of early degeneration, which is critical to support a paradigm shift of OA management from palliation of late disease towards prevention through early diagnosis and early treatment/interventions. Cartilage MR T1ρ and T2 measures have been shown to be promising imaging biomarkers for early cartilage degeneration. However, many challenges remain to clinically applying these techniques, including lack of standardized acquisition and analysis methods, long acquisition time, and uncertainty of variations between different MR systems. In this study, we will develop novel accelerated T1ρ and T2 imaging methods, implement these techniques on MR systems of three major vendors (Siemens, GE and Philips), systematically evaluate inter-vendor inter-site variation of these measures using dedicated T1ρ and T2 calibration phantoms (to be developed in this study) and traveling subjects, investigate the source(s) and magnitude of the differences, explore methods to mitigate the variability, and demonstrate the feasibility of the newly developed acceleration techniques to quantify cartilage degeneration longitudinally in a multi-vendor setting. Successful implementation of the proposed study will provide a full package of T1ρ and T2 imaging that will be ready for dissemination and will help to pave the way towards large-scale multi-vendor, multi-site trials using T1ρ and T2 imaging, facilitate clinical translation of these quantitative MR techniques, and ultimately transform patient management of OA and other disorders using quantitative imaging biomarkers.

项目概要/摘要 MRI 弛豫测量已应用于改善多种疾病的早期诊断和预后。 然而，将定量 MRI 整合到临床方案中的一个典型障碍是采集时间长。 此外，调查跨站点的量化变异性是一个重要但有时被忽视的步骤 和 MR 系统，以验证 MR 成像生物标志物并将这些措施应用于大规模多 供应商多站点试验。具体而言，缺乏对供应商间、站点间差异的系统评估。 T1ρ 成像，尽管它已广泛应用于神经、肝脏、心脏、肿瘤和肌肉骨骼领域 （MSK）成像。商业 T1ρ 模型均不可用。拟议的研究正在解决这些问题 显着差距，旨在开发和交叉验证 MR 上的新型快速 MR T1ρ 和 T2 成像方法 来自多个供应商的系统，然后对有骨关节炎风险的患者进行可行性评估。骨关节炎 (OA) 影响着美国超过 2700 万人。尽管目前尚无缓解 OA 疾病的药物 (DMOAD) 广泛的努力。开发 DMOAD 的障碍之一是缺乏敏感且可靠的非侵入性生物标志物 可以在短时间内检测治疗效果。此类生物标志物也将有利于临床实践 通过识别有患 OA 风险或处于疾病早期阶段的患者，当行为改变时 策略被证明对于减缓疾病进展最有效。有一个紧迫的、未满足的 临床需要对早期退化进行强有力的评估，这对于支持 OA 范式转变至关重要 通过早期诊断和早期治疗，从缓解晚期疾病转向预防管理 治疗/干预。软骨 MR T1ρ 和 T2 测量已被证明是有前途的成像 早期软骨退化的生物标志物。然而，这些技术的临床应用仍面临许多挑战 缺乏标准化的采集和分析方法、采集时间长等 不同 MR 系统之间变化的不确定性。在这项研究中，我们将开发新型加速 T1ρ 和 T2 成像方法，在三大供应商（西门子、GE 和 Philips），使用专用的 T1ρ 和 T2 系统地评估这些措施的供应商间站点间差异 校准体模（将在本研究中开发）和旅行受试者，调查来源和 差异的大小，探索减轻变异性的方法，并证明该方法的可行性 新开发的加速技术可在多供应商中纵向量化软骨退化 环境。拟议研究的成功实施将提供完整的 T1ρ 和 T2 成像包， 将准备好传播，并将有助于为大规模多供应商、多站点试验铺平道路 使用 T1ρ 和 T2 成像，促进这些定量 MR 技术的临床转化，并最终 使用定量成像生物标志物改变 OA 和其他疾病的患者管理。